Polaryx Therapeutics, Inc. Common Stock Market Cap ($87.23 Million)
Market Cap & Net Worth: Polaryx Therapeutics, Inc. Common Stock (PLYX)
Polaryx Therapeutics, Inc. Common Stock market cap. Polaryx Therapeutics, Inc. Common Stock (NASDAQ:PLYX) has a market capitalization of $87.23 Million ($87.23 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19529 globally and #4485 in its home market, demonstrating a -9.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Polaryx Therapeutics, Inc. Common Stock's stock price $1.75 by its total outstanding shares 49845993 (49.85 Million).
Polaryx Therapeutics, Inc. Common Stock Market Cap History (2026–2026)
Polaryx Therapeutics, Inc. Common Stock market cap history from 2026 to 2026. Data shows growth from $87.23 Million to $87.23 Million (0.00% CAGR). Check PLYX stock price for real-time trading data and today's change.
Polaryx Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Polaryx Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see how efficiently does Polaryx Therapeutics, Inc. Common Stock generate cash for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PLYX by Market Capitalization
Companies near Polaryx Therapeutics, Inc. Common Stock in the global market cap rankings as of October 31, 2026. See Polaryx Therapeutics, Inc. Common Stock balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Polaryx Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Polaryx Therapeutics, Inc. Common Stock (2026–2026)
Market capitalization of Polaryx Therapeutics, Inc. Common Stock from 2026 to today. Between 2026 and today, Polaryx Therapeutics, Inc. Common Stock's market cap moved from $87.23 Million to $ 87.23 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $87.23 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Polaryx Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $87.23 Million USD |
| MoneyControl | $87.23 Million USD |
| MarketWatch | $87.23 Million USD |
| marketcap.company | $87.23 Million USD |
| Reuters | $87.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more